Kidney: Renal cell carcinoma with t(6;11)(p21;q12) MALAT1/TFEB by Argani, Pedram & Ladanyi, Marc
Solid Tumour Section 
Short Communication 
Atlas Genet Cytogenet Oncol Haematol. 2017; 21(9) 340 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
INIST-CNRS OPEN ACCESS JOURNAL 
Kidney: Renal cell carcinoma with 
t(6;11)(p21;q12) MALAT1/TFEB 
Pedram Argani, Marc Ladanyi 
Department of Pathology, The Johns Hopkins Hospital, Baltimore MD (PA) pargani@jhmi.edu; Dept. 
of Pathology, , MSKCC, 1275 York Avenue, New York, NY 10021 (ML) USA. 
Published in Atlas Database: August 2016 
Online updated version : http://AtlasGeneticsOncology.org/Tumors/RenalCellt0611ID5011.html 
Printable original version : http://documents.irevues.inist.fr/bitstream/handle/2042/68544/08-2016-RenalCellt0611ID5011.pdf 
DOI: 10.4267/2042/68544
This article is an update of : 
Argani P, Ladanyi M. Kidney: t(6;11)(p21;q12) in renal cell carcinoma. Atlas Genet Cytogenet Oncol Haematol 2005;9(3) 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2017 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
Abstract 
Review on Renal cell carcinoma with 
t(6;11)(p21;q12) MALAT1/TFEB, with data on 
clinics, and the genes involved. 
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Identity 
Other names 
Alpha-TFEB renal cell carcinoma 
Note 
A distinctive renal neoplasm with epithelioid 
morphology, basement membrane production focal 
HMB45 immunoreactivity. 
Classification 
The t(6;11) renal cell carcinomas (RCCs) harbor a 
specific Alpha (MALAT1)-TFEB gene fusion. Xp11 
translocation RCCs harbor gene fusions involving 
TFE3 transcription factor. TFEB and TFE3 belong 
to the same MiT subfamily of transcription factors. 
Because of similarities at the clinical, morphologic, 
immunohistochemical, and genetic levels, the Xp11 
translocation RCCs and t(6;11) RCCs are currently 
grouped together under the category of MiT family 
translocation renal cell carcinoma. 
Clinics and pathology 
Etiology 
Not clear, but a subset of confirmed cases have 
occurred in children who were exposed to prior 
cytotoxic chemotherapy, raising the possibility that 
this tumor may be induced by chemotherapy. 
Epidemiology 
There are approximately 50 reported cases, the Male: 
Female ratio is 1.4:1. The median age is 31 years 
(range: 3-68 years). 
Pathology 
On microscopic examination, these neoplasms 
feature nests and tubules of polygonal epithelioid 
cells, separated by thin capillaries. Papillary 
architecture may be seen. The majority of the tumor 
cells have abundant clear to granular eosinophilic 
cytoplasm, well-defined cell borders and round 
nuclei with small nucleoli. However, a second 
population of smaller epithelioid cells is also 
characteristic, typically (but not always) clustered 
around nodules of hyaline basement membrane 
material within larger acini. Mitoses are rare and 
necrosis is usually absent. The cases examined have 
generally been negative for cytokeratins by 
immunohistochemistry, but all have labeled at least 
focally for HMB45 and Melan A. The t(6;11) renal 
carcinomas demonstrate specific nuclear labeling for 
TFEB protein by IHC while other neoplasms  
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and normal tissues do not. Hence, nuclear labeling 
for TFEB is a sensitive and specific diagnostic 
marker for this renal neoplasm with a TFEB gene 
fusion. TFEB break-apart FISH is generally more 
reliable in variably-fixed archival material. 
Treatment 
Nephrectomy 
Prognosis 
Unclear at the current time. One case has 
metastasized and killed the patient, proving that 
these are malignant neoplasms. 
Genes involved and 
proteins 
TFEB (transcription factor EB) 
Location 6p21.1 
DNA / RNA 
TFEB has 10 exons, with the ATG protein initiation 
codon located within exon 3. 
Protein 
TFEB is a transcription factor with a basic helix-
loop-helix DNA binding domain, a leucine zipper 
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dimerization domain18, and a nuclear localization 
signal, thought to be located C-terminal to the helix-
loop-helix domain. TFEB is ubiquitously expressed. 
TFEB, TFE3, TFEC and Mitf comprise the members 
of the microphthalmia transcription factor 
subfamily, which have homologous DNA binding 
domains and can bind to a common DNA sequence. 
These four transcription factors may homo- or 
heterodimerize to bind DNA, and they may have 
functional overlap. 
MALAT1 (metastasis associated lung 
adenocarcinoma transcript 1 (non-
protein coding)) 
Location 11q13.1 
Protein 
MALAT1 (Alpha) is an intronless, untranslated gene 
of unknown function. 
Result of the chromosomal 
anomaly 
Hybrid Gene 
Description 
The breakpoint on TFEB is within its second intron, 
just upstream of the TFEB initiation ATG codon, 
which results in retention of the entire TFEB coding 
region in the fusion gene. Although the MALAT1 
promoter drives expression of the fusion gene, the 
MALAT1 gene does not contribute to the open 
reading frame. Therefore, the consequence of the 
MALAT1-TFEB fusion is dysregulated expression 
of the normal full-length TFEB protein. The TFEB-
MALAT1 fusion gene is also expressed. 
Detection 
RT-PCR is the standard molecular approach for 
detection of most translocation-associated gene 
fusions. This is because, in most leukemia and 
sarcoma translocations, genomic breakpoints are 
variably positioned within large introns, but the 
splicing of the transcripts encoded by fusion genes 
typically results in very consistent fusion points that 
can be tightly bracketed by appropriate primers to 
generate relatively small RT-PCR products (e.g. 
100-300 bp). 
In the t(6;11)(p21;q12), the lack of splicing between 
MALAT1 and TFEB results in a different and unique 
fusion transcript in each case that can vary 
considerably in size (over 1 kb) from case to case. 
Based on the sizes of these two breakpoint cluster 
regions, RT-PCR product sizes using a primer at the 
5' end of MALAT1 in combination with a reverse 
primer in exon 3 of TFEB could range in size to over 
1.5 kb. This is a technical drawback for molecular 
diagnosis that could be addressed by using several 
assays with different MALAT1 primers scattered 
from the 5' to the 3' end of the gene. However the 
unique features of the MALAT1 gene as a 
translocation partner should result in a lack of 
splicing across the intron rearranged by the 
translocation. Indeed, this seems to be the case, since 
in all three cases with data on both the genomic 
junction sequence and the fusion transcript, the 
sequences have been identical.  
This indicates that the DNA PCR and RT-PCR 
products will be identical if a reverse primer that 
binds to TFE3 exon 3 is used.  
Because it is easier to isolate and amplify 1 to 1.5 kb 
target DNAs from clinical tumor samples than target 
RNAs of the same size (given the greater lability of 
RNA), detecting this fusion by long range DNA PCR 
may be a useful alternative for molecular diagnosis. 
Fusion Protein 
Note 
The MALAT1-TFEB gene fusion results in 
dysregulated expression of native TFEB protein. 
Description 
TFEB protein that is overexpressed as a result of the 
MALAT1-TFEB gene fusion localizes to the nucleus 
as determined by immunohistochemistry. While it is 
ubiquitously expressed, native TFEB in cells without 
this translocation is not detectable by this assay. 
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